Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Device Design & Manufacturing
crbard.com

See what CB Insights has to offer

Investments

3

Portfolio Exits

1

Partners & Customers

1

About C.R. Bard

C. R. Bard (NYSE: BCR), is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the fields of Vascular, Urology, Oncology, and Surgical Specialties. Bard markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities.

C.R. Bard Headquarter Location

730 Central Avenue

New Providence, New Jersey, 07974-1199,

United States

908-277-8000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing C.R. Bard

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find C.R. Bard in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

M

Medical Devices

3,383 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

Latest C.R. Bard News

Dentsply Sirona Provides Corporate Update

Apr 19, 2022

April 19, 2022 08:40 ET John Groetelaars Named Interim Chief Executive Officer Barbara Bodem Named Interim Chief Financial Officer Company Provides Update on Anticipated First Quarter Financial Results CHARLOTTE, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or “the Company”) (Nasdaq: XRAY) today announced the appointment of John Groetelaars, who serves on Dentsply Sirona’s Board of Directors, as Interim Chief Executive Officer. He succeeds Don Casey, who has been terminated as CEO and will cease to serve as a member of the Company’s Board, effective immediately. The Board has initiated a search to identify the Company’s next CEO and has retained a leading executive search firm to support the process. Eric Brandt, Non-Executive Chairman of the Board stated, “We are pleased to welcome John as Dentsply Sirona’s Interim CEO. John has a strong track record of driving innovative business strategies, and as a seasoned executive with more than 30 years of industry experience, he is uniquely positioned to lead our company during this transition period. John is the right leader to bring continuity and guide Dentsply Sirona’s execution of its key strategic initiatives to create sustainable value for our shareholders. As the Board conducts its search for a permanent CEO, we are focused on finding a candidate with a track record of world-class execution and operational expertise who can position the Company for the future.” Mr. Groetelaars commented, “I look forward to serving as Interim CEO during this important time for the Company. I joined the Company’s Board because of my deep appreciation for our mission and unwavering commitment to innovation, operational excellence and providing positive outcomes for patients and customers. Dentsply Sirona is situated in attractive, growing dental categories and has a strong foundation in place, built on its portfolio of leading products and differentiated position across key markets. The Board is confident that renewing the Company’s focus on execution will stabilize the business and deliver strong performance despite ongoing macroeconomic challenges. This will be my focus from day one, and I am prepared to leverage my prior executive leadership experience as I work with the rest of the Board and management team to drive the Company’s strategy and advance its vision to transform dentistry and improve oral health globally.” Mr. Brandt continued, “On behalf of the Board, I would like to thank Don for his many contributions to our company. Don has played a key role in strengthening our foundation and advancing our mission to create innovative solutions for healthy smiles. We wish him all the best in his future endeavors.” Appointment of Interim CFO Dentsply Sirona also today announced the appointment of Barbara Bodem as Interim Chief Financial Officer, effective upon Jorge Gomez’s previously announced departure on May 6, 2022. Ms. Bodem will join the Company on April 25, 2022, and work closely with Mr. Gomez to ensure a seamless transition. Ms. Bodem is an accomplished executive with over two decades of financial leadership experience in the healthcare industry, most recently serving as Senior Vice President and CFO of Hillrom. Previously, Barbara served in senior leadership roles at Mallinckrodt Pharmaceuticals, Hospira and Eli Lilly and Company. Mr. Brandt said, “We are fortunate to welcome Barbara, a proven finance executive, as our interim CFO during this transition period. Barbara brings extensive expertise in healthcare with an international perspective, having served in multiple leadership roles across finance organizations at global companies. As we continue our search for a permanent CFO, we believe that Barbara and our talented financial team will continue to deliver value for our patients, business partners and shareholders.” Select Preliminary Financial Results for the First Quarter of 2022 Dentsply Sirona today also provided an update on its anticipated financial results for the first quarter ending March 31, 2022. On a preliminary basis, the Company expects that net sales will be approximately $965 million (representing an organic sales decline of approximately 1.4% versus prior year). Additionally, GAAP diluted earnings per share will be in the range of $0.26 - $0.30 and adjusted earnings per share will be in the range of $0.48 - $0.52. Relative to last year, these results reflect weaker sales performance in the U.S., global supply chain challenges, and foreign exchange headwinds. The Company will provide further information on its results and 2022 outlook when it releases its earnings as scheduled on May 5, 2022. The amounts set forth above are preliminary estimates. The Company is in the process of finalizing its results of operations for the first quarter ended March 31, 2022 and therefore final results are not yet available. These preliminary estimates are based solely upon information available to management as of the date of this press release. The Company’s actual results may differ from these estimates due to the completion of its quarter-end closing procedures, final adjustments and developments that may arise or information that may become available between now and the time the Company’s financial results for the first quarter ended March 31, 2022 are finalized. The Company’s unaudited consolidated financial statements for the first quarter ended March 31, 2022 should be consulted once they become available. About John Groetelaars John Groetelaars served as President, CEO and a Board member at Hillrom from May 2018 until the company’s acquisition by Baxter International, Inc., in December 2021. At Hillrom, Mr. Groetelaars led a transformation of the business, successfully articulating and launching a new connected-care strategy and vision, growing the portfolio through seven acquisitions and one divestiture, and driving record financial performance. Prior to Hillrom, Mr. Groetelaars served as Executive Vice President and President of the Interventional Segment at Becton, Dickinson and Company following its acquisition of C.R. Bard Inc. He previously served in a variety of progressive roles at C.R. Bard during his 10-year career there, including as a group president from 2015 to 2017. Prior to joining C.R. Bard, Mr. Groetelaars held various international leadership positions in Canada, Denmark and the United Kingdom at Boston Scientific Corporation from 2001 until 2008. Prior to joining Boston Scientific, Mr. Groetelaars held positions in general management, marketing, business development and sales with Guidant Corporation and with Eli Lilly. Mr. Groetelaars earned a Bachelor of Science in Mechanical Engineering from Kettering University and an MBA from Columbia Business School. About Barbara Bodem Barbara Bodem most recently served as Senior Vice President and Chief Financial Officer for Hillrom, where she was responsible for both Financial and Information Technology and oversaw portfolio transformation and performance acceleration. She also served as Interim CIO during the pandemic. Prior to her positions at Hillrom, Ms. Bodem served as Senior Vice President of Finance for Mallinckrodt Pharmaceuticals, Vice President of Finance, Global Commercial Operations for Hospira, and at several positions of increasing responsibility at Eli Lilly and Company, culminating in Chief Financial Officer, Lilly Oncology. Ms. Bodem also has extensive Board experience, and currently serves as Audit Committee Chair for Turning Point Therapeutics, as a Director on Syneos’ Board, and as a Director on Enovis Corporation’s Board. She has also previously served as a board member for Invacare Corporation. Ms. Bodem earned and a Bachelor of Science in Finance with honors and minors in Economics and East Asian Studies, as well as an MBA from Indiana University. About Dentsply Sirona Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with a 135-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. As The Dental Solutions Company, Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better, safer and faster dentistry. The Company’s shares of common stock are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products. Non-GAAP Financial Measures The Company has provided certain measures in this press release that are not calculated in accordance with US GAAP and therefore represent Non-GAAP measures. These Non-GAAP measures may differ from those used by other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP. These Non-GAAP measures are used by the Company to measure its performance and may differ from those used by other companies. Management believes that these Non-GAAP measures are helpful as they provide another measure of the results of operations, and are frequently used by investors and analysts to evaluate the Company’s performance exclusive of certain items that impact the comparability of results from period to period, and which may not be indicative of past or future performance of the Company. The Company is not able to reconcile projected adjusted earnings per share (non-GAAP) to first quarter 2022 projected earnings per share (GAAP) without unreasonable efforts because it is not possible to predict with a reasonable degree of certainty the actual impact of the tax rate and related matters for the quarter ended March 31, 2022. The unavailable information could have a significant impact on the Company’s first quarter 2022 reported financial results. Forward-Looking Statements All statements in this press release that do not directly and exclusively relate to historical facts constitute “forward-looking statements.” These statements represent current expectations and beliefs, including statements regarding preliminary financial information for the first quarter ending March 31, 2022, and no assurance can be given that the results described in such statements will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. Furthermore, many of these risks and uncertainties are currently amplified by and may continue to be amplified by or may, in the future, be amplified by, the novel coronavirus (“COVID-19”) pandemic and the impact of varying private and governmental responses that affect our customers, employees, vendors and the economies and communities where they operate. For a written description of these factors, see the section titled “Risk Factors” in Dentsply Sirona’s Annual Report on Form 10-K for the most recent fiscal year. No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of press release or to reflect the occurrence of unanticipated events. Contact Information

C.R. Bard Investments

3 Investments

C.R. Bard has made 3 investments. Their latest investment was in Unisurge as part of their Series B on June 6, 1993.

CBI Logo

C.R. Bard Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/30/1993

Series B

Unisurge

$8.48M

No

1

4/1/1992

Series A

Subscribe to see more

$99M

Subscribe to see more

10

6/1/1991

Seed

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/30/1993

4/1/1992

6/1/1991

Round

Series B

Series A

Seed

Company

Unisurge

Subscribe to see more

Subscribe to see more

Amount

$8.48M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

C.R. Bard Portfolio Exits

1 Portfolio Exit

C.R. Bard has 1 portfolio exit. Their latest portfolio exit was C.R. Bard - Electrophysiology Business on November 01, 2013.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/1/2013

Divestiture

$99M

2

Date

11/1/2013

Exit

Divestiture

Companies

Valuation

$99M

Acquirer

Sources

2

C.R. Bard Acquisitions

17 Acquisitions

C.R. Bard acquired 17 companies. Their latest acquisition was LifeBond on January 15, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/15/2020

Series D

$99M

$67.5M

Acquired

1

1/22/2016

$99M

Acq - P2P

1

7/1/2015

Debt

$99M

$24.53M

Acquired

1

9/4/2013

Subscribe to see more

$99M

Subscribe to see more

10

8/20/2013

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

1/15/2020

1/22/2016

7/1/2015

9/4/2013

8/20/2013

Investment Stage

Series D

Debt

Other

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$67.5M

$24.53M

$99M

Note

Acquired

Acq - P2P

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

C.R. Bard Partners & Customers

1 Partners and customers

C.R. Bard has 1 strategic partners and customers. C.R. Bard recently partnered with Boston Scientific on October 10, 2014.

C.R. Bard Team

11 Team Members

C.R. Bard has 11 team members, including current President, Benson F Smith.

Name

Work History

Title

Status

Benson F Smith

President

Current

David Chazanovitz

President

Former

David Hemink

President

Former

Paul LaViolette

President

Former

John McDermott

President

Former

Name

Benson F Smith

David Chazanovitz

David Hemink

Paul LaViolette

John McDermott

Work History

Title

President

President

President

President

President

Status

Current

Former

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.